Based on RNAi technology, Remebee's active ingredients
are dsRNA formulated to silence Israeli Acute Paralysis
Virus (IAPV). It is delivered in feed and sustains colony health in
the presence of the virus.
Product Properties:
• Potent protection from Israel Acute Paralysis
Virus (IAPV)
• Potentially applicable to other bee viruses
• Inherent robustness precludes the possibility of the virus breaking
resistance
• Extreme specificity and no toxicity
• No residues in honey bees or honey
Product Status:
Beeologics has begun the regulatory approval process for Remebee in conjunction
with the Food and Drug Administration (FDA) after a period of assessment
with the IR4 agency and the Environmental Protection Agency (EPA). The
field trials conducted in Florida, Pennsylvania and Israel provided sufficient
data that led to the FDA permit of conducting a large scale clinical trial
in the United States. These trials are underway with the participation
of leading beekeepers across the United States.
